Press Release: Sanofi completes acquisition of DR-0201

Core Insights - Sanofi has completed the acquisition of DR-0201, now named SAR448501, from Dren Bio, enhancing its immunology pipeline and ambition to lead in the field of immunology [1][4] Group 1: Acquisition Details - The acquisition involved an upfront payment of $600 million, with potential future payments totaling $1.3 billion based on development and launch milestones [4] - Dren Bio will continue to operate independently to advance its pipeline of antibody therapeutics [4] Group 2: Product Information - SAR448501 is a targeted bispecific myeloid cell engager that has demonstrated robust B-cell depletion in pre-clinical and early clinical studies [2] - The product targets specific tissue-resident and trafficking myeloid cells to induce deep B-cell depletion through targeted phagocytosis [2] Group 3: Clinical Implications - Recent studies suggest that deep B-cell depletion may reset the adaptive immune system, potentially leading to sustained treatment-free remission in patients with refractory B-cell mediated autoimmune diseases, such as lupus [3]